The use of enteral antibiotics to prevent acute graft versus host disease (GvHD) has not been studied prospectively in children. We hypothesized the risk of GvHD in pediatric bone marrow transplant (BMT) recipients would be decreased with enteral metronidazole. Eligible subjects included pediatric patients referred to one center for first allogeneic BMT. Enteral metronidazole 20 mg/kg/day divided thrice daily (maximum 750 mg/day) was administered from day À14 to day þ 35. The risk of GvHD grade II or more severe among subjects treated with metronidazole was compared to historical controls. There were no significant differences between treated (n ¼ 19) and historical controls (n ¼ 83) with respect to age, gender, prophylaxis, or conditioning regimens, proportion receiving unrelated donor marrow, proportion receiving umbilical cord blood, or transplantation indication. The probability of remaining free of GvHD at day þ 100 was lower in the treated group (P ¼ 0.047). The adjusted relative risk of developing GvHD among subjects treated with metronidazole was 0.36 (95% CI: 0.13-0.997; P ¼ 0.05). Five patients were unable to complete the study; two were likely related to study medication. We conclude that enteral metronidazole appears effective in the prevention of GvHD. These results suggest that a randomized trial is justifiable in children, especially recipients of alternative donor BMT.
tive donor; metronidazole; intestinal flora; prevention Graft versus host disease (GvHD) is a significant cause of morbidity and mortality for patients undergoing allogeneic bone marrow transplantation (aBMT) for malignancy, primary immunodeficiency, and other genetic disorders. A variety of regimens have been used both to prevent and to treat GvHD. These include T-cell depletion, and systemic immunosuppression with agents such as cyclosporin and corticosteroids. In general, studies of GvHD treatment have shown that grade I-II gastrointestinal involvement and similar degrees of skin involvement are readily reversible with additional immunosuppression and do not significantly impact disease-free survival in related donor transplants. 1, 2 However, successful treatment of GvHD after unrelated donor transplants is less predictable. 3, 4 The occurrences of grade III-IV gut GvHD and grade II or more severe liver GvHD is associated with a much poorer long-term survival for all patients regardless of donor source (ie related, unrelated, or cord blood). Thus, because of the impact of GvHD on prognosis, more effective measures, such as the addition of enteral antibiotics to conventional immune suppression are needed to prevent the disease.
The rationale for using antibiotics to decontaminate the gut and prevent GvHD has evolved from several observations. In an animal model of GvHD, the median length of survival of mice given enteral antibiotics that then undergo experimental bone marrow transplantation is markedly prolonged compared to mice not given enteral antibiotics. 5 In a retrospective review of 194 bone marrow transplant recipients ages 15-57 years, Beelen et al 6 analyzed the association between decontamination of anaerobic fecal flora and the development of GvHD. Patients who experienced sustained suppression of intestinal anaerobic flora experienced lower rates of GvHD than patients whose flora were not suppressed. A subsequent open label clinical trial comparing ciprofloxacin to a combination of ciprofloxacin and metronidazole revealed that patients in the combination group had a lower incidence of GvHD than patients in the ciprofloxacin group. 7 These data support the hypothesis that intestinal bacteria play a role in the development of GvHD.
Patients younger than 15 years of age are unique, as ciprofloxacin is contraindicated in this age group, and children frequently undergo transplantation for unique disease processes. We conducted a pilot study to assess the feasibility and efficacy of enteral metronidazole for the prevention of graft versus host disease in a pediatric population. The use of metronidazole is attractive for several reasons. First, metronidazole is available as a liquid and can be readily administered to children. Second, there is some evidence that metronidazole has anti-inflammatory properties. 8, 9 Finally, metronidazole has been helpful in the treatment of Crohn's disease. [10] [11] [12] We hypothesized that administration of enteral metronidazole before and immediately following marrow transplantation would result in a reduced risk of GvHD.
Patients and methods
This was a single arm prospective study with historical controls. Patients were considered eligible if they were referred to our center for allogeneic marrow transplantation, were undergoing first transplantation, and enrolled prior to dayÀ14. Exclusion criteria included prior history of marrow transplantation or history of idiosyncratic reactions to metronidazole. Informed consent was obtained from the parents of participating subjects, and assent was obtained from subjects 12 years of age or older. To assess adverse events, three individuals (one transplant physician and one gastroenterologist, and one infectious disease physician) served as a data and safety monitoring board (DSMB). The criteria set forth by Freston were used to assess the causal relationship between the potential adverse event and study drug. 13 Metronidazole was administered to subjects at a dose of 20 mg/kg/day divided thrice daily up to a maximum dose of 750 mg/day, and therapy was initiated on day À14 and discontinued on day þ 35. Patients who were unable to swallow pills were given metronidazole suspension either by mouth or by an enteral feeding tube (nasogastric or nasojejunal). During their hospitalization for transplantation, patients were asked about vomiting and nausea, paresthesias, and examined for oral candidiasis.
The development of grade II or more severe graft versus host disease at day þ 100 was the primary study end point. Day þ 100 GvHD score was determined by consensus of BMT clinicians according to standard procedure independent of the study. Briefly, maximum grade of acute GvHD is assigned to each recipient of allogeneic BMT after they have achieved day 100 post transplant. At a monthly GvHD conference, all attending BMT physicians discuss evaluable patients utilizing retrospective review of weekly GvHD scores (previously assigned prospectively by the BMT attending staff physicians), taking into account relevant diagnostic biopsies, cultures for infectious agents and other pertinent studies. The acute GvHD information is then entered into the permanent database. Metronidazole was discontinued in patients who developed GvHD prior to the study end point.
For both subjects and controls, the following data were obtained: male gender (yes/no), transplantation for malignancy (yes/no), recipient of an umbilical cord blood transplant (yes/no), and unrelated donor status (yes/no). Conditioning regimens included chemotherapy only (yes/ no), chemotherapy plus low-dose total body irradiation (yes/no), and chemotherapy plus high-dose total body irradiation (yes/no). Four patients -all transplanted for severe combined immunodeficiency -did not receive conditioning. GvHD prophylaxis regimens included in vivo prophylaxis (cyclosporin, methotrexate, and/or antithymocyte globulin) only (yes/no), or in vivo prophylaxis plus T-cell depletion (yes/no). One child -transplanted for severe combined immunodeficiency -did not receive GvHD prophylaxis. In addition, age at transplantation was determined and included in the analysis. Because age at transplantation was not normally distributed (mean age 7.3 years, median 5.9 years) it was dichotomized in the analysis (age less than 5.9 years or age greater than or equal to 5.9 years).
Student's t and Fisher's exact tests were used to compare continuous and categorical variables, respectively. The cumulative probability of developing GvHD among subjects and historical controls was compared using the product-limit method. To assess for potential confounding variables, we used proportional hazards regression. All covariates were entered into the model in the forms discussed above. We used stepwise selection, with a significance of a P-value less than 0.1 to remain in the model. Of note, two variables -in vivo immunosuppression only and partial T-cell depletion plus in vivo immunosuppression -were mutually exclusive variables. Therefore, only prophylaxis in vivo immunosuppression only was included in the final multivariate model. When in vivo immunosuppression plus partial T-cell depletion was included in the model, and in vivo immunosuppression only was excluded, the parameter estimates, significance values and hazard ratios were virtually identical (data not shown). For all analyses, all subjects who received enteral metronidazole were included in the analysis. Subjects unable to complete the study were censored at the time of their withdrawal. Of note, two patients were withdrawn from the study due to persistent emesis; both later developed GvHD. These subjects were treated as failures. For both the product-limit and proportional hazards analyses, time at risk began on the day of transplantation. Data were analyzed using SAS Version 8.2 s (SAS Institute, Cary, NC, USA)
Results
A total of 22 subjects were enrolled in the study. Two patients received no study drug due to parental choice, and one enrolled patient did not undergo marrow transplantation during the study period. A total of 19 subjects are therefore included in the analysis. There were no significant differences between subjects and historical controls with respect to age at transplantation, gender, proportion of unrelated donor recipients, proportion of umbilical cord blood recipients, prophylaxis or conditioning regimens, or the proportion of individuals transplanted for malignancy ( Table 1) .
The cumulative probability of remaining GvHD free was greater among subjects than historical controls (Figure 1 ). In the univariate analysis (Table 2) , only prophylaxis with in vivo immunosuppression (HR ¼ 2.55; 95% CI 1.33-4.90) and partial T-cell depletion plus in vivo immunosuppression (HR ¼ 0.42; 95% CI 0.22-0.80) were statistically associated with a risk in GvHD. Enteral metronidazole was associated with a borderline decreased risk of GvHD (HR ¼ 0.37; 95% CI 0.13-1.03).
The results of the multivariable analysis are shown in Table 3 . Following adjustment for unrelated donor status, prophylaxis with in vivo immunosuppression only, and age greater than or equal to 5.9 years, the relative risk of developing GvHD among subjects treated with metronidazole was 0.36 (95% CI: 0.13-0.997; P ¼ 0.05).
A total of five patients were withdrawn from the study. In three patients, all enteral medications were discontinued for clinical indications unrelated to the study. These patients were included in the analysis as censored observations on the day of withdrawal. Three adverse events were deemed 'possibly' or 'probably' related by the DSMB, two of which resulted in withdrawal of study subjects. One subject developed persistent nausea and vomiting that resolved after discontinuation of metronidazole, and eventually developed grade II GvHD. This subject was treated as a failure; however, the DSMB deemed this adverse event as 'probably related' to the study medication. One patient developed prolonged persistent emesis, was treated for engraftment syndrome, and later developed gastrointestinal GvHD. This subject was treated as a failure. The DSMB deemed this adverse event as 'possibly related' to the study medication. One subject developed paresthesias on day þ 30, in association with erythema of lower extremities and pitting edema. Metronidazole was . 'x' marks censored observations. P ¼ 0.047 (log-rank). 
discontinued in this patient on day þ 35 per the study protocol, and the symptoms persisted following discontinuation of metronidazole. These were successfully managed with oral gabapentin. The DSMB deemed this event either 'possibly related or 'probably related'. There were no cases of thrush; all allogeneic recipients routinely received daily prophylaxis with fluconazole.
Discussion
In this pilot study, enteral metronidazole was associated with a lower risk of grade II or more severe GvHD following allogeneic bone marrow transplantation. This lower risk was statistically significant following adjustment for potential confounding variables, including the use of aggressive GvHD prophylaxis, unrelated donor status, and age at transplantation. Furthermore, enteral metronidazole was well tolerated. These results support the initiation of a randomized trial to establish enteral metronidazole's efficacy in GvHD prophylaxis and safety for clinical use in children.
The causative role of intestinal flora in the development of acute GvHD has been supported by animal and human studies. Beelen et al 6 demonstrated 1.7-fold increase in the risk of grades II-IV GvHD among patients with persistent anaerobic fecal flora demonstrated in stool following antimicrobial therapy. A subsequent trial by the same group reported a two-fold increase in grades II-IV GvHD in patients given ciprofloxacin alone compared to those given ciprofloxacin plus metrondiazole. 7 Interestingly, the benefit of ciprofloxacin and metronidazole was observed in HLA-identical sibling donor marrow recipients.
We also observed a reduction in the risk of grades II-IV GvHD among subjects following adjustments for other potential confounding variables. The studies by Beelen et al and ours support the role of intestinal flora as a causative factor in the generation of GvHD. One potential mechanism to explain this observation has been suggested. 14, 15 Pretransplantation conditioning causes gastrointestinal tissue damage and translocation of lipopolysaccharide (LPS) from the GI tract. The subsequent proinflammatory cytokine response serves to activate donor T cells, thereby amplifying the signal that leads to acute GvHD. Our study was not designed to specifically address the influence of conditioning regimens on the risk of GvHD, but we assessed the potential role for conditioning regimens on the risk of GvHD, and did not find a relationship.
Metronidazole predominantly covers anaerobic bacteria. Here, we demonstrate that the administration of enteral metronidazole reduces of the risk of graft versus host disease, and we presume this is due to a reduction in the numbers of bacteria and therefore the amount of LPS. What is less clear is which bacteria are elaborating LPS. Our data indicate that it is predominantly anaerobic bacteria, and this is consistent with one previous prospective study demonstrating the reduction in risk of GvHD with selective anaerobic decontamination. 6 Metronidazole is also effective in Crohn's disease -a disorder in which interaction between the intestinal flora and the gastrointestinal tract is associated with disease. 11, 12 It is also unclear what anti-inflammatory effect metronidazole may have when administered orally. At least one study using an animal model demonstrated that metronidazole has an anti-inflammatory effect, 9 but this observation has not been consistent. 16 A total of five patients were withdrawn from the study. Three were withdrawn for reasons unrelated to the study. Two had nausea and emesis, and were subsequently determined to have GvHD. One patient experienced paresthesias while receiving metronidazole. Duffy et al 17 reported 14 patients who had developed peripheral neuropathy associated with metronidazole for Crohn's disease. It is possible that paresthesias experienced by our patient were due to metronidazole. However, this subject's symptoms were associated with erythema and edema, associations that have not -to our knowledgebeen reported with metronidazole neuropathy. Moreover, all of the subjects in the study by Duffy received metronidazole for greater than 4 months, with cumulative doses of greater than 90 g, a dose duration approximately twice as long and a cumulative dose almost three times greater than our subject. Finally, the peripheral neuropathy associated with metronidazole is usually mild and reversible with discontinuation of the drug, although resolution may take several months. 17, 18 The development of paresthesias in patients receiving metronidazole should be further assessed as a potential adverse effect if a larger trial is undertaken.
Strengths of our study are the inclusion of children, rigorous data analysis to assess the role of potential confounding variables, and the use of a DSMB. The previous trial performed by Beelen et al excluded patients younger than 15 years of age. Children are unique, as they require specific dosing adjustments, are transplanted for unique indications (ie immunodeficiencies), and many may need enteral feeding tubes to administer nutrition and medications. Indeed, the majority of our study patients had enteral feeding tubes in place, part of the transplant protocol at CCHMC.
Despite these strengths, there are several limitations. First, we did not correlate intestinal decontamination with efficacy. Second, the primary outcome measure, grade II-IV GvHD was assigned by unblinded clinicians. Third, our control group was historical, and it is difficult to determine whether improvements in care during these different time periods accounted for the difference seen in the study population. We do not believe this latter limitations explains the observed difference in risk between the two groups, as the clinical care encompassing the time periods between both groups varied little. Finally, metronidazole is commonly prescribed, and it is possible that some patients in the historical control group received metronidazole for variable periods during their transplantation course. This latter limitation is likely not an issue, as metronidazole administration would be associated with a reduced rate of GvHD, thereby biasing the risk of GvHD towards the null hypothesis.
Enteral metronidazole administered from day À14 through day þ 35 appears to be effective in reducing the risk of grade II-IV GvHD, and is well tolerated. The results of this study combined with data from studies in adults justify a randomized clinical trial in children.
